Raymond James Financial’s Evogene EVGN Stock Holding History

Raymond James Financial’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-200	Closed	-$256	–	5532
2025 Q2	$256	Buy	+200	New	+$245	﹤0.01%	6753

Other funds holding EVGN

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Raymond James Financial's EVGN Position: Q3 2025 in Review

Raymond James Financial sold out of Evogene (EVGN) in Q3 2025, closing a stake of 200 shares — an estimated $256 sold.

Raymond James Financial first reported a position in EVGN in Q2 2025 and held it in 1 quarter. The position peaked at $256 in Q2 2025. 14 funds tracked by Wall St. Rank hold EVGN as of Q3 2025.

Raymond James Financial reported no remaining Evogene position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 200 Evogene shares in Q3 2025, an estimated $256.
Raymond James Financial first reported a position in Evogene in Q2 2025 and held it in 1 quarter.
Raymond James Financial's Evogene position peaked at $256 in Q2 2025.
14 funds tracked by Wall St. Rank held Evogene as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.